Drug - Nuedexta (dextromethorphan hydrobromide/quinidine) [Avanir Pharmaceuticals]
March 2011
Patient has pseudobulbar affect (PBA) and none of the exclusion criteria listed below. A six month initial PA will be given.
Prescriber must provide documentation of benefit, which should include at least a measure of the PBA episodes showing a reduction over time.
Nuedexta is FDA approved for the treatment of pseudobulbar affect (PBA), a condition characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state.
Capsules of dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg.
Starting dose: One capsule daily by mouth for 7 days.
Maintenance dose: After 7 days, 1 capsule every 12 hours.
MHCP Provider Call Center 651-431-2700 or 800-366-5411